Fludarabine with Myeloablative Timed-Sequential Busulfan in Older Patients: Results of a Randomized Phase II Clinical Trial

BACKGROUND: Hematopoietic stem cell transplantation (HCT) conditioning regimens that can reduce relapse risk without increasing non-relapse mortality (NRM) are needed. We tested the safety of timed-sequential delivery of myeloablative dose of busulfan in older patients and younger patients with como...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Haematol
Main Authors: Popat, Uday R., Mehta, Rohtesh S., Bassett, Roland, Chen, Julianne, Valdez, Benigno C., Kawedia, Jitesh, Ahmed, Sairah, Alousi, Amin M, Anderlini, Paolo, Al-Atrash, Geath, Bashir, Qaiser, Ciurea, Stefan O., Hosing, Chitra M., Im, Jin S., Jones, Roy, Kebriaei, Partow, Khouri, Issa, Marin, David, Nieto, Yago, Olson, Amanda, Oran, Betul, Parmar, Simrit, Rezvani, Katayoun, Qazilbash, Muzaffar H., Shah, Nina, Srour, Samer A., Shpall, Elizabeth J, Champlin, Richard E., Andersson, Borje S
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6317874/
https://ncbi.nlm.nih.gov/pubmed/30389035
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(18)30156-X
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados